{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:05:34Z","timestamp":1779951934143,"version":"3.53.1"},"reference-count":105,"publisher":"Informa UK Limited","issue":"5","funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Investigational Drugs"],"published-print":{"date-parts":[[2026,5,4]]},"DOI":"10.1080\/13543784.2026.2660911","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T17:41:27Z","timestamp":1776966087000},"page":"303-314","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Isatuximab: an anti-CD38 therapy that addresses unmet needs and mechanisms of resistance in multiple myeloma"],"prefix":"10.1080","volume":"35","author":[{"given":"Yuxin","family":"Liu","sequence":"first","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton","family":"Mo","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shonali","family":"Midha","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique","family":"Hartley-Brown","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]},{"name":"Brigham and Women\u2019s Hospital","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Lee","sequence":"additional","affiliation":[{"name":"Sarah Cannon Research Institute","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Franz","sequence":"additional","affiliation":[{"name":"Hackensack University Medical Center","place":["Hackensack, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taylor","family":"Nicholson","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taya Jamal","family":"Salman","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Fortune","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Rifkin","sequence":"additional","affiliation":[{"name":"Yampa Valley Medical Center","place":["Steamboat Springs, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Merz","sequence":"additional","affiliation":[{"name":"University of Michigan","place":["Ann Arbor, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Greco-Hainsworth Tennessee Oncology Centers for Research","place":["Nashville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Laubach","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"O\u2019Gorman","sequence":"additional","affiliation":[{"name":"Mater Misericordiae University Hospital","place":["Dublin, Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Richardson","sequence":"additional","affiliation":[{"name":"Harvard Medical School","place":["Boston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,5,4]]},"reference":[{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae321"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-024-00529-7"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.70067"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-025-01041-x"},{"key":"e_1_3_4_7_1","unstructured":"With permission from the NCCN clinical practice guidelines in oncology (NCCN Guidelines\u00ae) for multiple myeloma V.5.2026. \u00a9 National Comprehensive Cancer Network Inc; 2026. All rights reserved. cited 2026 Jan 20. To view the most recent and complete version of the guideline go online to NCCN.org."},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2018.09.001"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12020407"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6619"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02134"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1379738"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-740944"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-0695"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01771"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121522"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121527"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12389"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3474.3474"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021012448"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008209"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-019-0198-4"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0857-2"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00478-4"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12561"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12666"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-740787"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33448"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-02-895193"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-023-01936-7"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70041"},{"key":"#cr-split#-e_1_3_4_32_1.1","unstructured":"ClinicalTrials.gov [Internet]. Study of isatuximab combined with bortezomib + cyclophosphamide + dexamethasone (VCD) and bortezomib + lenalidomide + dexamethasone (VRD) in newly diagnosed multiple myeloma (MM) non eligible for transplant or no intent for immediate transplantation. NCT02513186. 2024 [updated 2024 Jan 29"},{"key":"#cr-split#-e_1_3_4_32_1.2","unstructured":"cited 2025 Jul 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02513186"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2025.01.022"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00744"},{"key":"#cr-split#-e_1_3_4_35_1.1","unstructured":"ClinicalTrials.gov [Internet]. Multicenter phase 2 study of subcutaneous isatuximab plus bortezomib lenalidomide and dexamethasone in the treatment of newly diagnosed transplant ineligible multiple myeloma. NCT05889221. 2024 [updated 2024 Sep 5"},{"key":"#cr-split#-e_1_3_4_35_1.2","unstructured":"cited 2025 Jul 5]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05889221"},{"key":"#cr-split#-e_1_3_4_36_1.1","unstructured":"ClinicalTrials.gov [Internet]. Lenalidomide bortezomib and dexamethasone induction therapy with either intravenous or subcutaneous isatuximab in patients with newly diagnosed multiple myeloma. NCT05804032. 2025 [updated 2025 Mar 7"},{"key":"#cr-split#-e_1_3_4_36_1.2","unstructured":"cited 2025 Jul 5]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT05804032"},{"key":"#cr-split#-e_1_3_4_37_1.1","unstructured":"ClinicalTrials.gov [Internet]. Iberdomide vs. iberdomide plus isatuximab maintenance therapy post ASCT in newly diagnosed multiple myeloma. NCT06216158. 2025 [updated 2025 Dec 3"},{"key":"#cr-split#-e_1_3_4_37_1.2","unstructured":"cited 2025 Dec 22]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06216158"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-025-01436-0"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2022.2095949"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0536-3"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-3192"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.268656"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1597"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024028107"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221107850"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00760"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2025-3932"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-022-04917-5"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00643-3"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2019.2019.0061"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2022.106948"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-631200"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1983427"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.20106"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.287904"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02206-w"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2018.04.007"},{"issue":"1","key":"e_1_3_4_59_1","first-page":"887","article-title":"Isatuximab, bortezomib, lenalidomide, dexamethasone (ISA-VRD) in patients with transplant-ineligible (TI) newly diagnosed myeloma (NDMM) and plasmacytomas: IMROZ subgroup analysis","volume":"9","author":"Zamagni E","year":"2025","unstructured":"Zamagni E, Facon T, Dimopoulos MA, et al. Isatuximab, bortezomib, lenalidomide, dexamethasone (ISA-VRD) in patients with transplant-ineligible (TI) newly diagnosed myeloma (NDMM) and plasmacytomas: IMROZ subgroup analysis. Hemasphere. 2025;9(S1):887\u2013888. Abstract PF750.","journal-title":"Hemasphere"},{"key":"e_1_3_4_60_1","unstructured":"Recordati Rare Diseases. ENJAYMO\u00ae (sutimlimab). Prescribing information. 2024. Available from: https:\/\/enjaymo.com\/wp-content\/themes\/enjaymo-dtc\/assets\/pdf\/enjaymo_PI.pdf"},{"key":"e_1_3_4_61_1","unstructured":"Genentech. PIASKY\u00ae (crovalimab). Prescribing information. 2024. Available from: https:\/\/www.gene.com\/download\/pdf\/piasky_prescribing.pdf"},{"key":"e_1_3_4_62_1","unstructured":"Novartis. FABHALTA\u00ae (iptacopan). Prescribing information. 2025. Available from: https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/fabhalta.pdf"},{"key":"e_1_3_4_63_1","unstructured":"Alexion Pharmaceuticals. VOYDEYA\u00ae (danicopan). Prescribing information. 2024. Available from: https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2024\/english\/voydeya_uspi.pdf"},{"key":"e_1_3_4_64_1","unstructured":"Alexion Pharmaceuticals. ULTOMIRIS\u00ae (ravulizumab). Prescribing information. 2024. Available from: https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2024\/english\/ultomiris_uspi.pdf"},{"key":"e_1_3_4_65_1","unstructured":"Apellis Pharmaceuticals. EMPAVELI\u00ae (pegcetacoplan). Prescribing information. 2025. Available from: https:\/\/pi.apellis.com\/files\/PI_Empaveli.pdf"},{"key":"e_1_3_4_66_1","unstructured":"Alexion Pharmaceuticals. SOLIRIS\u00ae (eculizumab). Prescribing information. 2025. Available from: https:\/\/alexion.us\/-\/media\/alexion_global\/documents\/regulatory\/north-america\/usa\/2024\/english\/soliris_uspi.pdf"},{"key":"e_1_3_4_67_1","unstructured":"Regeneron. VEOPOZ\u00ae (pozelimab). Prescribing information. 2024. Available from: https:\/\/www.regeneron.com\/downloads\/veopoz_fpi.pdf"},{"key":"e_1_3_4_68_1","unstructured":"UCB Inc. ZILBRYSQ\u00ae (zilucoplan). Prescribing Information. 2025. Available from: https:\/\/www.ucb-usa.com\/zilbrysq-prescribing-information.pdf"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-703439"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.279459"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32556-5"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-021-00146-4"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400712"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-023-00797-8"},{"key":"e_1_3_4_75_1","unstructured":"Sanofi-Aventis U.S. LLC. SARCLISA\u00ae (isatuximab). Prescribing Information. 2025. Available from: https:\/\/products.sanofi.us\/Sarclisa\/sarclisa.pdf"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2026.2646947"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01696"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03050-2"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7502"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00263-0"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026230"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.284325"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02264-3"},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00070-X"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00347-8"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(25)03450-0"},{"key":"#cr-split#-e_1_3_4_87_1.1","unstructured":"ClinicalTrials.gov [Internet]. A study to investigate subcutaneous isatuximab in combination with weekly carfilzomib and dexamethasone in adult participants with relapsed and\/or refractory multiple myeloma (SubQSA). NCT06356571. 2025 [updated 2026 Jan 8"},{"key":"#cr-split#-e_1_3_4_87_1.2","unstructured":"cited 2025 Nov 5]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06356571"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.7517"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.8029"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2022.280660"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32030182"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2152-2650(21)02323-5"},{"issue":"1","key":"e_1_3_4_93_1","first-page":"446","article-title":"Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma and soft-tissue plasmacytomas: ICARIA-MM subgroup analysis","volume":"4","author":"Beksac M","year":"2020","unstructured":"Beksac M, Richardson PG, Unal A, et al. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed\/refractory multiple myeloma and soft-tissue plasmacytomas: ICARIA-MM subgroup analysis. Hemasphere. 2020;4(S1):446. EP978.","journal-title":"Hemasphere"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.287200"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03143"},{"key":"e_1_3_4_96_1","unstructured":"European Medicines Agency. Sarclisa: EPAR; 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/sarclisa#authorisation-details"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.11.002"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2024.02.004"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/10717544.2025.2484278"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03485-7"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0141-0"}],"container-title":["Expert Opinion on Investigational Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543784.2026.2660911","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T06:51:22Z","timestamp":1779951082000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543784.2026.2660911"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,4]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,4]]}},"alternative-id":["10.1080\/13543784.2026.2660911"],"URL":"https:\/\/doi.org\/10.1080\/13543784.2026.2660911","relation":{},"ISSN":["1354-3784","1744-7658"],"issn-type":[{"value":"1354-3784","type":"print"},{"value":"1744-7658","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieid20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-02-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}